Carnosine as a potential therapeutic for the management of peripheral vascular disease.

Jack Feehan, Rohit Hariharan, Timothy Buckenham, Charles Handley, Aruni Bhatnagar, Shahid Pervez Baba, Barbora de Courten

Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD 2022;32(10):2289-2296

PMID: 35973888

Abstract

AIMS

To evaluate the potential role of carnosine in the management of peripheral vascular disease.

DATA SYNTHESIS

Peripheral vascular disease is growing in its burden and impact; however it is currently under researched, and there are a lack of strong, non-invasive therapeutic options for the clinicians. Carnosine is a dipeptide stored particularly in muscle and brain tissue, which exhibits a wide range of physiological activities, which may be beneficial as an adjunct treatment for peripheral vascular disease. Carnosine's strong anti-inflammatory, antioxidant and antiglycating actions may aid in the prevention of plaque formation, through protective actions on the vascular endothelium, and the inhibition of foam cells. Carnosine may also improve angiogenesis, exercise performance and vasodilatory response, while protecting from ischemic tissue injury.

CONCLUSIONS

Carnosine may have a role as an adjunct treatment for peripheral vascular disease alongside typical exercise and surgical interventions, and may be used in high risk individuals to aid in the prevention of atherogenesis.

CLINICAL RECOMMENDATION

This review identifies a beneficial role for carnosine supplementation in the management of patients with peripheral vascular disease, in conjunction with exercise and revascularization. Carnosine as a supplement is safe, and associated with a host of beneficial effects in peripheral vascular disease and its key risk factors.

Copyright © 2022 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Address: Institute for Health and Sport, Victoria University, Footscray, VIC, Australia.; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton VIC, Australia.; Christchurch Clinical School of Medicine University of Otago and Christchurch Hospital, Christchurch, New Zealand.; Diabetes and Obesity Center, Christina Lee Brown Environment Institute, University of Louisville, Louisville, KY, USA.; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton VIC, Australia; School of Health and Biomedical Sciences, RMIT, Bundoora. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.